Human Genome Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Human Genome Sciences, Inc.
Industry reps are glad that Birenbaum, who was the chief cannabis policy advisor to the governors of New York and Rhode Island, was given a prominent role at FDA that could spur regulatory action.
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
Minute Insight: FundamentalVR Raises $20M In Series B, Further Develop HapticVR For Surgical Training
Fundamental VR, which developed a virtual surgical platform that uses advanced technologies such as haptic (touch) feedback, announced on 11 August it raised $20m in a series B round led by EQT Life Sciences and prior investors Downing Ventures.
Pfizer recorded the largest quarterly sales in its history as its COVID-19 franchise easily outweighed the currency issues that are challenging other companies. But expectations for a quick end to the pandemic have wiped these gains from Pfizer’s stock price.